The time factor in oncology: Consequences on tumour volume and therapeutic planning

Journal of Experimental and Clinical Cancer Research

Volumn 25, Issue 4, 2006, Pages 557-573

  Creton, Giovanni ^a   Benassi, Mi ^a   Di Staso, M ^a   Ingrosso, G ^a   Giubilei, C ^a   Strigari, L ^b  

^a CIRAD   (France)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cytotoxic therapies; Doubling time; Gompertz's model; IORT; Neoplastic growth; Time interval

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; GROWTH CURVE; HEAD AND NECK TUMOR; HUMAN; INTRAOPERATIVE RADIOTHERAPY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; TIME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

CELL DIVISION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM STAGING; NEOPLASMS; TIME FACTORS;

EID: 33846478655     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Schmidt C.: The Gompertzian View: Norton Honored for Role in Establishing Cancer Treatment Approach J. Natl. Cancer Inst. 96: 1492-1493, 2004
2. Donovan J. C. H., Slingerland J., Tannock J.: Cell proliferation and tumour growth. In Tannock J. F., Hill R.P., Bristow R.G., Harrington L. The basic science of oncology. New York, Mcgrowth Hill, 2004, 167-194.
3. Huchet A, Caudry M, Belkacemi Y, Trouette R, Vendrely V, Causse N, Recaldini L, Atlan D, Maire JP. Effet volume en radiothérapie [II]. Deuxième partie: volume et tolérance des tissus sains. Cancer Radiothérapie 5: 353-36, 2003.
4. Skipper H.E., Schabel F.M. Jr., Wilcox W.S.: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1-111; 1964.
5. Giordano M., Danova M., Mazzini G., Gobbi P., Riccardi A.: Cell kinetics with in vivo bromodeoxyuridine assay, proliferating cell nuclear antigen expression and flow cytometric analysis. Prognostic significance in acute nonlymphoblastic leukemia. Cancer 71:2739-45; 1993.
6. Skipper H.E.: Laboratory models: some historical perspective. Cancer. Treat. Rep. 70:3-7; 1986.
7. Simpson-Herren L., Lloyd H.H.: Kinetic parameters and growth curves for experimental tumor systems. Cancer Chemother. Rep. 54: 143-74, 1970.
8. Shackney S.E., McCormack G.W., Guchural G.J. Jr.: Growth rate patterns of solid tumors and their relation to responsiveness to therapy. An analytical review. Ann. Intern. Med. 89: 107-21, 1978.
9. Begg A.C., Steel G.G.: Cell proliferation and growth rate of tumours. In: Steel GG eds Basic Clinical radiobiology. New York Edward Arnold. 2002: 8 23.
10. Collins V.P., Loeffler K., Tivey H.: Observations on growth rates of human tumors. Am. J. Radiol. 76: 988; 1956.
11. Steel G.G.: Cell survival as determinant on tumour response. Basic Clinical radiobiology. Steel GG eds Basic Clinical radiobiology. New York Edward Arnold. 2002, 52-64.
12. Tubiana M.: Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 28: 113-21, 1989.
13. Demicheli R.: Growth of testicular neoplasm lung metastases: tumor-specific relation between two Gompertzian parameters. Eur J Cancer 16:1603-8, 1980.
14. Spratt J.S., Greenberg R.A., Heuser L.S.: Geometry, growth rates and duration of cancer and carcinoma in situ of the breast before detection by screening. Cancer Res. 46: 970-4, 1986.
15. Sullivan P.W., Salmon S.E.: Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51: 1697-708, 1972.
16. Laird A.K.: Dynamics of growth in tumors and normal organisms. Natl. Cancer Inst. Monogr. 30: 15-28, 1969.
17. Norton L.: Mathematical interpretation of tumor growth kinetics. In: Greenspan EM, editor. Clinical interpretation and practice of cancer chemotherapy. New York: Raven; 1982, 53 70.
18. Norton L. Introduction to clinical aspects of preneoplasia. A mathematical relationship between stromal paracrine autonomy and population size. In: Marks PA, Turler H, Weil R, editors. Challenges of modern medicine. Vol. 1. Precancerous lesions. A multidisciplinary approach. Milan (Italy): Ares-Serono Symposia; 1993, 269-75.
19. Norton L.: Kinetic concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 26:11-20, 1999.
20. Norton L.A.: Gompertzian model of human breast cancer growth. Cancer Res. 48: 70-77, 1988.
21. Norton L., Simon R.: Growth curve of an experimental solid tumor following radiotherapy. J. Natl. Cancer Inst. 58: 1735-41, 1977.
22. Norton L., Simon R.: Tumor size, sensitivity to therapy, and the design of treatment schedules. Cancer Treat. Rep. 61: 1307-17, 1977.
23. Fletcher G.H.: Clinical dose response of human malignant epithelial tumours. Br. J. Radiol. 46: 1-12, 1973.
24. Suit HD.: Basic principles of radiotherapy-Radiation biology. In Fletcher GH Editor. Textbook of radiotherapy 3rd edition. Philadelphia, Lea& Febiger; 1980, 180-218.
25. Bernier J., Bataini J.T.: Regional outcome in head and neck cancer treated with high dose radiotherapy analysis of neck disease response in 1646 cases. Radiother. Oncol. 6: 87-103, 1986.
26. Fischer J.J.: Theoretical considerations in the optimisation of dose distribution in radiation therapy. Br. J. Radiol. 42; 925-30, 1969.
27. Schiff P.B., Harrison L.B., Strong E.W., Pass D.E., Shah J.P., Spiro R., Sessions R., Gerold F., Vikram B., Fuks Z.Y.: Impact of the time interval between surgery and postoperative radiation therapy on locoregional control in advanced head and neck cancer. J. Surg. Oncol. 43:203-208, 1990.
28. Muriel V.P., Tejada M.R., de Dios Luna del Castillo J.: Time-dose relationships in postoperatively irradiated patients with head and neck squamous cell carcinomas. Radiother. Oncol. 60: 137-145; 2001.
29. Waaijer A., Terhaard C.H., Dehnad H., Hordijk G.J., van Leeuwen M.S., Raaymakers C.P., Lagendijk J.J.: Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother. Oncol. 66: 271-276, 2003.
30. Dische S. Tumour growth while waiting: does it really matter? Clin. Oncol. 12: 139, 2000.
31. Fortin A, Bairati I, Albert M, et al. Effect of treatment delay on outcome of patients with early-stage head-and-neck carcinoma receiving radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 52:929-936, 2002.
32. O'Rourke N., Edwards R.: Lung cancer treatment waiting times and tumour growth. Clin. Oncol. 12:141-4, 2000.
33. Ang K.K., Trotti A., Brown B.W., Garden A.S., Foote R.L., Morrison W.H., Geara F.B., Klotch D.W., Goepfert H., Peters L.J.: Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51:571-8, 2001.
34. Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le Fur R.: Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. Int. J. Radiat. Oncol. Biol. Phys. 49:139-46, 2001.
35. Fowler J.F.: How worthwhile are short schedules in radiotherapy? A series of exploratory calculations. Radiother. Oncol. 18, 165-81, 1990.
36. Denekamp J.: Cell kinetics and radiation biology. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 2, 357-80, 1986.
37. Wilson G. D., McNally N.J., Dische S., Saunders M.I., Des Rochers C., Lewis A.A., Bennett M.H.: Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Brit. J. Cancer 58, 423-31, 1988.
38. Bennett M.H., Wilson G.D., Dische S., Saunders M.I., Martindale C.A., Robinson B.M., O'Halloran A.E., Leslie M.D., Laing J.H.: Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Brit. J. Cancer 65, 870-78, 1992.
39. Tubiana M.: Repopulation in human tumours. A biological background for fractionation in radiotherapy. Acta Oncol. 27:83-88, 1988.
40. Trott K.R., Kummermehr J.: What is known about tumour proliferation rates to choose between accelerated fractionation and hyperfractionation? Radiother. Oncol. 3:1-9, 1985.
41. Trott K.R., Kummermehr J.: Rapid repopulation in radiotherapy: a debate on mechanism. Accelerated repopulation in tumors and normal tissues. Radiother. Oncol. 22:159-60, 1991.
42. Barton M.B., Keane T.J., Gadalla T., Maki E.: The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother. Oncol. 23: 137-143, 1992.
43. Taylor J.M., Withers H.R., Mendenhall W.M.: Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother. Oncol. 17:95-102, 1990.
44. Withers H.R., Peters L.J., Taylor J.M., Owen J.B., Morrison W.H., Schultheiss T.E., Keane T., O'Sullivan B., van Dyk J., Gupta N. et al.: Local control of carcinoma of tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int. J. Radiat. Oncol. Biol. Phys. 33:549-562, 1995
45. Yang Y., Xing L.: Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology. Med. Phys. 32:3666-77, 2005
46. Brenner D.J.: Dose, Volume, and tumour-control predictions in radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 26: 171-9, 1993.
47. Tubiana M., Dutreix J., Wanbersie A.: Introduction to radiobiology. London Taylor and Francis, 1990, 179.
48. Fletcher G.H.: Textbook of radiotherapy radiotherapy- 3rd ed. Philadelphia: Lea& Febiger 1980, 180.
49. Hill R.P., Stanley J.A.: Pulmonary metastases of the Lewis lung tumor cell kinetics and response to cyclophosphamide at different sizes. Cancer. Treat. Rep. 61:29-36, 1977.
50. Peters L.J., Ang K.K., Thames H.D.: Altered fractionation schedules. In: Perez C.A., Brady L.W., (eds). Principles and practice of radiation oncology, 2nd ed., pp. 97-113, Philadelphia. PA: J. B. Lippincot 1992.
51. Peters L.J.: The efficacy of postoperative radiotherapy for advanced head and neck cancer: quality of evidence. Int. J. Radiat. Oncol. Biol. Phys. 40: 527-8, 1998.
52. Mackillop W.J., Fu H., Quirt C.F., Dixon P., Brundage M., Zhou Y.: Waiting for radiotherapy in Ontario. Int. J. Radiat. Oncol. Biol. Phys. 30:221-8, 1994.
53. Huang J., Barbera L., Brouwers M., Browman G., Mackillop W.J.: Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J. Clin. Oncol. 21:555-63, 2003.
54. Tubiana M.: The role of local treatment in the cure of cancer. Eur. J. Cancer 12: 2061-2069, 1992.
55. Leibel S.A., Scott C., Mohiuddin M., Marcial V., Coia L., Davis L., Fuks Z.: The effect of locoregional control in distant metastatic dissemination in carcinoma of the head and neck: result of analysis from the RTOG database. Int. J. Radiat. Oncol. 21:549-56, 1991.
56. Tubiana M.: The 1987 Franz Buschke lecture: the role of radiotherapy in the treatmment of chemosensitive tumours: Int. J Radiat. Oncol. Biol. Phys. 16: 763-74, 1989.
57. Tubiana M.: Is organe salvage in advanced disease possibile? In C. J. Rosenthal and M. Rotman Eds, Infusion chemotherapy Irradiation Interactions Elsevier Science B.V., 1998: 155-164.
58. Withers H.R., Peters L.J., Taylor J.M.G.: Dose-response relashionship for radiation therapy of subclinical disease. Int. J Radiat. Oncol. Biol. Phys. 31:353-9, 1995.
59. Withers H.R., Suwinski R.: Radiation dose response for subclinical metastases. Semin. Radiat. Oncol. 8:224-228, 1998.
60. Cividalli A., Cretan G., Ceciarelli F., Strigari L., Tirindelli Danesi D., Benassi M.: Influence of Time Interval between Surgery and Radiotherapy on Tumor Regrowth. J. Exp. Clin. Cancer Res., 24: 109-116, 2005.
61. Denekamp J., Hirst, D.G.: Radiation Science: Of Molecules, Mice and Men. J. Denekamp and D.G. Hirst Eds. British Institute of Radiology, London, 1992: 1-224.
62. Suwinski R., Sowa A., Rutkowski T., Wydmanski J., Tarnawski R., Maciejewski B.: Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int. J. Radiat. Oncol. Biol. Phys. 56: 399-412, 2003
63. Le Q.T., Fu K.K., Kroll S., Ryu J.K., Quivey J.M., Meyler T.S., Krieg R.M., Phillips T.L.: Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 39: 115-26, 1997.
64. Johnson C.R., Thames H.D., Huang D.T., Schmidt-Ullrich R.K.: The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int. J. Radiat. Oncol. Biol. Phys. 33:281-87, 1995.
65. Norton L.: Adjuvant breast cancer therapy: Current status and future strategies-growth kinetics and the improved drug therapy of breast cancer. Semin. Oncol. 26(suppl 3):1-4, 1999.
66. Hebert-Croteau N., Freeman C.R., Latreille J., Brisson J.: Delay in adjuvant radiation treatment and outcomes of breast cancer-a review. Breast Cancer Res. Treat. 74:77-94, 2002.
67. Kozusko F., Bajzer Z.: Combining Gompertzian growth and cell population dynamics. Math. Biosci. 185:153-67, 2003.
68. Norton L.: Use of dose-dense chemotherapy in the management of breast cancer. Clin. Adv. Hematol. Oncol. 4: 36-37, 2006.
69. Norton L.: Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol., 24 (S10): 3-10, 1997.
70. Orecchia R., Veronesi U.: Intraoperative electrons. Semin. Radiat. Oncol. 15:76-83, 2005.
71. Suit H.: Assessment of the impact of local control on clinical outcome. In: Meyer J.L., Purdy J.A., (eds.) 3-D Conformal Radiotherapy. Karger, 1996, 17-23.
72. Larsen M.P., Eisenberg M.S., Cummins R.O., Hallstrom A.P.: Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann. Emerg. Med. 22: 1652-1658, 1993.
73. Rumi M.N., Deol G.S., Bergandi J.A., Singapuri K.P., Pellegrini V.D. Jr.: Optimal timing of preoperative radiation for prophylaxis against heterotopic ossification. J Bone Joint Surg. Am. 87:366-73, 2005.
74. Kal H.B., Veen R.E.: Biologically effective doses of postoperative radiotherapy in the prevention of keloids. Dose-effect relationship. Strahlenther. Onkol. 181: 717-23, 2005.